Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement: This practice statement has been endorsed by The North American Menopause Society

Abstract

•Treatment or prevention of gynecologic cancer often results in induced menopause significantly impacting quality of life. •Hormone therapy is underutilized in in these settings despite more severe symptoms with induced menopause. •The risk/benefit profile of HT is favorable in most EOC, early stage endometrial, and cervical cancer. •HT is not recommended in women with advanced EC, uterine sarcoma, endometrioid or low grade serous ovarian cancer. •Lynch syndrome patients and BRCA mutation carriers without history of breast cancer may also use HT to improve QOL.